^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Multiple Myeloma

    20h
    A Phase I Study of SHR-3836 in Patients With Multiple Myeloma (clinicaltrials.gov)
    P1, N=99, Not yet recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd.
    New P1 trial
    23h
    DSP-5336-101: A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) (clinicaltrials.gov)
    P1/2, N=606, Recruiting, Sumitomo Pharma America, Inc. | N=362 --> 606
    Enrollment change
    |
    FLT3 (Fms-related tyrosine kinase 3) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • NPM1 (Nucleophosmin 1) • KMT2A (Lysine Methyltransferase 2A)
    |
    FLT3-ITD mutation • FLT3 mutation • NPM1 mutation
    |
    Venclexta (venetoclax) • Xospata (gilteritinib) • azacitidine • enzomenib (DSP-5336)
    2d
    Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma (clinicaltrials.gov)
    P1, N=20, Recruiting, Washington University School of Medicine | Not yet recruiting --> Recruiting
    Enrollment open
    |
    clonoSEQ
    |
    Xpovio (selinexor)
    2d
    Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=54, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended
    Trial suspension
    |
    KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    NRAS mutation
    |
    TruSight Oncology 500 Assay
    |
    Gomekli (mirdametinib) • sirolimus
    2d
    Evaluating the Impact of a 12-month Multi-Modal Lifestyle Management Intervention on Disease Relevant Biomarkers (clinicaltrials.gov)
    P=N/A, N=67, Not yet recruiting, Hackensack Meridian Health | Trial completion date: Feb 2028 --> May 2028 | Trial primary completion date: Feb 2028 --> May 2028
    Trial completion date • Trial primary completion date
    3d
    ReSPECT: Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (clinicaltrials.gov)
    P3, N=602, Completed, Mundipharma Research Limited | Active, not recruiting --> Completed
    Trial completion
    |
    Chr del(5q)
    3d
    ICON: Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone (clinicaltrials.gov)
    P2, N=60, Recruiting, Amsterdam UMC, location VUmc | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cyclophosphamide • carfilzomib • iberdomide (CC-220)
    4d
    EAY131-C2: Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2) (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, National Cancer Institute (NCI) | N=35 --> 20 | Trial completion date: Feb 2026 --> Dec 2026
    Enrollment change • Trial completion date
    |
    MET exon 14 mutation
    |
    Xalkori (crizotinib)
    4d
    MMExFFPE: Multiple Myeloma Extramedulary Disease Samples FFPE (clinicaltrials.gov)
    P=N/A, N=15, Not yet recruiting, BIWAKO | Trial completion date: Jul 2026 --> Oct 2026 | Initiation date: Jan 2026 --> Jun 2026 | Trial primary completion date: Mar 2026 --> Jul 2026
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    SDC1 (Syndecan 1)
    4d
    Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) (clinicaltrials.gov)
    P1, N=40, Not yet recruiting, Washington University School of Medicine | Trial completion date: Jul 2028 --> Nov 2028 | Initiation date: Jan 2026 --> May 2026 | Trial primary completion date: Oct 2027 --> Feb 2028
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    clonoSEQ
    |
    Carvykti (ciltacabtagene autoleucel) • Hyleukin-7 (efineptakin alfa)
    4d
    CC-220-MM-001: A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=466, Active, not recruiting, Celgene | Trial completion date: Feb 2028 --> Jul 2028
    Trial completion date
    |
    bortezomib • carfilzomib • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • iberdomide (CC-220)
    5d
    Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant (clinicaltrials.gov)
    P2, N=120, Recruiting, University of Utah | Suspended --> Recruiting
    Enrollment open
    |
    CD34 (CD34 molecule)